Purpose Autoimmune diseases are thought to be caused by a loss of self-tolerance of the immune system. One candidate marker of immune dysregulation in autoimmune disease is the presence of increased double negative T cells (DNTs) in the periphery. DNTs are characteristically elevated in autoimmune lymphoproliferative syndrome, a systemic autoimmune disease caused by defective lymphocyte apoptosis due to Fas pathway defects. DNTs have also been found in the peripheral blood of adult patients with systemic lupus erythematosus (SLE), where they may be pathogenic. DNTs in children with autoimmune disease have not been investigated. 
Introduction
Systemic pediatric autoimmune diseases result from failure of immunologic tolerance leading to response against self [1] . While systemic autoimmunity affects many children, immune dysregulation mechanisms remain poorly understood.
A potential marker of disease and immunoregulatory defects in systemic lupus erythematosus (SLE) are circulating double negative T cells (DNTs) [2] . DNTs are mature postthymic T cells that express CD3/TCRα/β receptor but lack CD4/CD8 [3] . Patients with FAS/FAS ligand defects develop autoimmune lymphoproliferative syndrome (ALPS) with significant DNT accumulation, signifying escaped peripheral tolerance [4] [5] [6] . Importantly, in ALPS, somatic FAS mutations in DNTs results in similar clinical symptoms as germline mutations suggesting a pathogenic role [7, 8] .
Adults with SLE have elevated DNTs, and studies have suggested DNTs may be pathogenic [9] [10] [11] [12] . However, while DNTs have been associated with many disease processes, their precise role is uncertain [13, 14] . DNTs in pediatric autoimmune disease have not been evaluated. We hypothesize that DNTs may contribute to pediatric autoimmunity and investigated the frequency and phenotype in this population.
Materials and Methods

Subjects
Pediatric patients (≤21 years old) from a single institution diagnosed by a pediatric rheumatologist with SLE [15] , mixed connective tissue disease (MCTD), ANA positive oligoarticular or polyarticular juvenile idiopathic arthritis (JIA) [16] , or an elevated antinuclear antibody (ANA) ≥1:1,280 without systemic autoimmune disease were included in this study. No patients met classification criteria for ALPS [5] . Control subjects (≤25 years old) were healthy without autoimmunity. Washington University School of Medicine Human Research Protection Office approved this study.
Flow Cytometry
Peripheral blood mononuclear cells (PBMC) were isolated from whole blood (Ficoll-Paque), pre-incubated with mouse IgG (Sigma, St. Louis, MO), and stained for TCRγ/δ (clone: 11 F2), CD4 (RPA-T4), CD8 (HIT8a), and CD19 (SJ25C1) (BD Biosciences, San Jose, CA); TCRα/β (IP26) and CD3 (OKT-3) (e-Biosciences, San Diego, CA); and CD56 (N901; Beckman Coulter, Brea, CA). T, B, and natural killer (NK) cell percentages were calculated with standard gating strategies. − . DNT percentages greater than or equal to 2.5 % were considered elevated based upon previous studies [5, 17] . For patients with more than one visit, DNT percentages and absolute lymphocyte count are from the time of study entry.
Sequencing
Patient DNA was isolated from peripheral blood or saliva and the sequence of promoter regions, exons, and intron/ exon junctions of FAS determined by Sanger sequencing using primers previously described [18] . Sequences were compared to the reference FAS sequence (NCBI accession NG_009089) for variation and frequency of single nucleotide polymorphisms (SNPs) in dbSNP (http://www.ncbi.nlm. nih.gov/SNP/).
Phenotyping of DNTs
PBMCs were surface-stained with anti-TCRα/β/TCRγ/δ/ CD3/CD4/CD8/CD56 and anti-CD25 (BC96), CD45RA (HI100), CD45RO (UCHL1), CD69 (FN50) or HLA-DR (G46-6), (Biolegend, San Diego, CA). For intracellular staining, cells were fixed and permeabilized (BD Biosciences, San Jose, CA), and stained with granzyme B (GB12; Invitrogen, Grand Island, NY) or perforin (dG9; Biolegend, San Diego, CA). FoxP3 staining (206D; Biolegend, San Diego, CA) was performed as per manufacturer's recommendations (eBioscience, San Diego, CA).
Statistical Analysis
Statistical analysis was performed utilizing GraphPad Prism 6.0 (GraphPad Software Inc, La Jolla, CA). Specific tests are noted with results and/or in the figure legend. A p-value <0.05 was considered statistically significant.
Results
DNTs were evaluated in 82 subjects, 54 cases and 28 controls (Supplemental Table 1 ). The majority were Caucasian (62.2 %) and female (79.3 %), with a mean age 15 ± 5 years. Controls were slightly older than cases (p=0.001). To ensure there was no significant difference in DNT staining of PBMC versus whole blood, as has been reported for other immune cell types [19] , staining of PBMC and whole blood was compared in 4 age-matched normal donors and found to be similar (Supplemental Fig. 1) .
A higher percentage of pediatric patients with autoimmune disease had elevated DNTs>2.5 % compared to controls (p= 0.008, Fig. 1a ; Fischer's exact test). Eight of 23 patients (34.8 %) with SLE, 20.0 % (3/15) with JIA, 27.3 % (3/11) with elevated ANA, and 40.0 % (2/5) with MCTD had increased DNTs (Fig. 1b) . While no patients met criteria for ALPS, the coding and regulatory regions of FAS was sequenced in 15 of the subjects (14 cases and one control) with elevated DNTs and available DNA. No insertions/deletions were found, and only previously reported SNPs with allele frequencies >1.5 % were identified (data not shown), suggesting that no subjects had pathogenic FAS mutations.
Absolute percentages of DNTs and most other lymphocytes were not different across patient populations (Supplemental Table 2 ) with the exception of differences in the mean percentages of B cells (p=0.02) and CD56 + CD3
+ cells (p= 0.002) between groups by ANOVA.
DNT percentages did not appear to change with medication as there was no statistically significant difference in the percentage of patients with elevated DNTs when compared to medication usage (Fig. 1c) . We collected multiple samples from 16 patients over an average of 8 months and most had relatively stable DNTs above/below 2.5 % (Fig. 1d) . We also investigated whether increased DNTs were associated with lymphopenia, as previously suggested [20] and found no association (r=−0.11, p=0.45, Fig. 1e ).
Additional cell surface markers and intracellular proteins in DNTs and single positive CD4/CD8 T cells were evaluated in five autoimmune patients with DNTs >2.5 % (DNT hi ), five with autoimmunity and DNTs <2.5 % (DNT lo ), and five healthy controls (Fig. 2a-h ). DNTs from DNT hi cases showed increased CD45RA expression compared to healthy control DNTs (p= 0.008, Fig. 2c ), but not DNT lo patients. DNT CD45RA expression from DNT hi cases was similar to that seen in CD8 cells, and higher than CD4 cells (p=0.008). Whereas, DNT CD45RO expression from DNT hi cases was also similar to CD8 cells (Fig. 2d) , but lower than CD4 cells (p=0.008).
Discussion
This is the first study to evaluate DNTs in pediatric autoimmunity. Significantly more patients had DNTs elevated ≥2.5 % compared to controls. Additionally, DNTs were stable over 8 months, suggesting that single observations are significant. Medications did not correlate with DNT%, similar to previous adult lupus studies [2, 11] . The presence of elevated DNTs in cases not on cytotoxic treatment also suggests that elevated DNTs are due to autoimmunity and not secondary to medication.
There is limited knowledge about the relationship between DNT percentages and absolute lymphocyte count. Some prior reports suggest that a false negative elevation of DNTs is possible in a lymphopenic state due to inaccurate flow cytometry quantification [20] . By evaluating a large number of pediatric patients with autoimmune disease, our study demonstrates that DNT percentage do not correlate with the absolute lymphocyte count in children.
We analyzed various phenotypic and activation markers in DNTs. CD25, FoxP3, CD69, HLA-DR, perforin and granzyme B were not significantly elevated in DNTs. While DNTs appear to lack common markers found in T regulatory cells (e.g., CD25, FoxP3), a previous in vitro study showed that DNTs might have suppressive activity by cell contact [12] . We observed that DNTs from children with autoimmunity are predominantly CD45RA + , consistent with a previous study of DNTs in ALPS [21] . This could indicate lack of prior antigen exposure, up regulation of CD45RA similar to effector memory T cells [22] , or physiology similar to end-stage T cells which are effective in cytokine secretion and cytoxicity [23] . Increased DNT CD45RA expression was also seen in adult SLE patients [11] . Interestingly, the C45RA/RO DNT expression pattern in DNT hi patients was similar to CD8 cells, consistent with a proposed common lineage [24] .
The role of DNTs in autoimmunity remains incompletely understood. DNTs in patients with ALPS are likely pathogenic, or the end result of pathogenic cells, based on somatic FAS mutations selectively in DNTs [8] . In vitro, CD8 cell derived DNTs, are pro-inflammatory and produce IL-1β, IL-17, and IFN-γ [25] . Studies of in situ kidney DNTs from patients with SLE demonstrated IL-17 production that might contribute to lupus nephritis and induce Th17 cell differentiation [9, 26] . By contrast, other reports of regulatory DNTs suggest some cells may play beneficial roles by suppressing auto-reactive CD8 cells [27] . Our findings demonstrate that DNTs are elevated in pediatric patients with several types of autoimmune disease, and in patients with high ANAs but no overt autoimmunity, and it remains to be determined whether DNTs contribute to underlying disease. Future investigations are important in elucidating DNT function, understanding their role in autoimmunity, and potentially providing novel therapeutic targets.
